Order byBest matchMost fresh

Hims, Eli Lilly Weight-Loss Drugs

Digest more
Top News
Impacts
Zepbound and Mounjaro will cost $1,899 per month through Hims, while liraglutide will cost $299, according to the company's website.
From Investopedia
Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025.
From U.S. News & World Report

Read more on News Digest

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on se
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Why Hims & Hers Health Stock Soared Tuesday
Hims & Hers revealed Tuesday that it will begin offering branded versions of Eli Lilly's tirzepatide -- the active ingredient in weight loss
Lilly sues two compounders over copies of weight-loss drugs
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
Eli Lilly Threatens Obesity Drug Copycat Makers After Shortage
Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans Tuesday to file two lawsuits and send about fifty cease-and-desist letters.
Eli Lilly takes actions to stop compounders from making its weight loss med
Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is the active ingredient in Zepbound for weight loss and Mounjaro for type 2 diabetes.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.
Explore more
Eli Lilly's weight loss drug Mounjaro launched in India; check prices, how it works
Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken once every week and will be available in 2.5mg and 5 mg vials. Read on to know its prices and how the weight loss drug works.
Eli Lilly may manufacture weight-loss drug Mounjaro in India in future, says CEO David Ricks
Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO
Eli Lilly First to Launch Weight Loss Drug in Obesity-Hit India
Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a country that has the world’s third-largest number of obese people.
Eli Lilly Launches weight-loss drug Mounjaro in India
Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and obesity drug market.
Feedback